Hims & Hers Health (NYSE:HIMS) Downgraded by Zacks Research to “Strong Sell”

Posted by Francis Steltz on Jun 10th, 2026

Zacks Research lowered shares of Hims & Hers Health (NYSE:HIMS – Free Report) from a hold rating to a strong sell rating in a research report released on Monday,Zacks.com reports.

Several other equities research analysts have also recently weighed in on the stock. Weiss Ratings cut shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research report on Tuesday, May 12th. BTIG Research reiterated a “neutral” rating on shares of Hims & Hers Health in a research report on Tuesday, May 12th. Bank of America lowered their price target on shares of Hims & Hers Health from $28.00 to $25.00 and set a “neutral” rating for the company in a research report on Tuesday, May 26th. Morgan Stanley decreased their price objective on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Finally, Barclays lifted their price target on shares of Hims & Hers Health from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, March 11th. Four equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $28.70.

Check Out Our Latest Report on HIMS

Hims & Hers Health Trading Up 6.8%

Shares of HIMS stock opened at $29.02 on Monday. Hims & Hers Health has a 12-month low of $13.74 and a 12-month high of $70.43. The company has a market capitalization of $6.72 billion, a P/E ratio of -322.40, a P/E/G ratio of 50.98 and a beta of 2.37. The firm has a 50-day moving average price of $24.93 and a 200 day moving average price of $26.91. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The firm had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. During the same period in the prior year, the business earned $0.20 earnings per share. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. Research analysts forecast that Hims & Hers Health will post 0.04 earnings per share for the current fiscal year.

Insider Activity

In other news, Director David B. Wells acquired 48,400 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was acquired at an average price of $24.23 per share, with a total value of $1,172,732.00. Following the completion of the transaction, the director directly owned 224,417 shares of the company’s stock, valued at $5,437,623.91. This trade represents a 27.50% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Soleil Boughton sold 9,463 shares of the company’s stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $30.00, for a total transaction of $283,890.00. Following the sale, the insider directly owned 299,368 shares of the company’s stock, valued at $8,981,040. This represents a 3.06% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 212,807 shares of company stock worth $5,473,644. 11.76% of the stock is owned by company insiders.

Institutional Trading of Hims & Hers Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HIMS. Binnacle Investments Inc acquired a new stake in shares of Hims & Hers Health during the 3rd quarter worth approximately $28,000. Silicon Valley Capital Partners acquired a new stake in shares of Hims & Hers Health during the 3rd quarter worth approximately $48,000. Flagship Harbor Advisors LLC acquired a new stake in shares of Hims & Hers Health during the 4th quarter worth approximately $28,000. Bogart Wealth LLC grew its position in shares of Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after buying an additional 632 shares during the period. Finally, Smartleaf Asset Management LLC grew its position in shares of Hims & Hers Health by 44.7% during the 3rd quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock worth $54,000 after buying an additional 283 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.